Evaluation of [18F]APN-1607 as a PET Biomarker for Longitudinal Change in Tau Pathology in Participants With Progressive Supranuclear Palsy
Latest Information Update: 12 Oct 2023
At a glance
- Drugs Florzolotau (Primary)
- Indications Progressive supranuclear palsy
- Focus Diagnostic use
- Sponsors Invicro
- 06 Oct 2023 Planned End Date changed from 1 Jun 2023 to 1 Jun 2024.
- 06 Oct 2023 Planned primary completion date changed from 1 Jun 2023 to 1 Jun 2024.
- 01 Jul 2022 Planned primary completion date changed from 1 Jun 2022 to 1 Jun 2023.